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Abstract: Although systemic absorption of estrogen with local treatment for vulvovaginal 
atrophy (VVA) is most likely to be negligible, it is unknown whether this minimal absorption 
will affect outcomes in women with breast cancer. Use of adjuvant therapy with aromatase 
inhibitors for breast cancer is associated with high incidence of VVA symptoms. Because of the 
impact of moderate to severe VVA symptoms on the quality of life in breast cancer survivors, 
there has been an intense search for alternative therapies. Further, the publicity that followed the 
publication of data from the Women’s Health Initiative Study has led to the suggestion by the 
medical community to use the lowest dose therapy possible for minimal time duration in order 
to avoid risks. This article will highlight the progress in alternative therapies for VVA.
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Introduction
In general, only 20%–25% of symptomatic women seek medical help for the treat-
ment of vulvovaginal atrophy (VVA), despite the availability of US Food and Drug 
Administration–approved treatment. The fear of breast cancer associated with the 
prescription of hormone therapy (HT) is the main reason for lack of acceptance of HT 
by most women. Even clinicians are asking whether it is time to stop prescribing even 
short courses of such treatment in view of the recent publication linking menopausal 
HT with breast cancer.1 The American College of Obstetricians and Gynecologists 
opined that “HT use should be limited to the treatment of menopausal symptoms at the 
lowest effective dosage over the shortest duration possible and continued use should 
be reevaluated on a periodic basis.”2
On average, women have safety concerns about the prescription of HT even at the 
lowest effective dosage over the shortest duration possible. The results of a survey 
that evaluated the prevalence and impact of VVA symptoms and perceptions about 
safety of HT among women were reported at the North American Menopause Society 
(NAMS) annual meeting in 2008; of the 2290 respondents, 45% of women said that 
they experience or had experienced symptoms of VVA.3 The most common symptoms 
were vaginal dryness, pain, irritation, and itching. HT-related safety concerns were the 
main reason for discontinuance of HT or it never having being used among respondents. 
For those women using HT, a third expressed concerns about its long-term safety and 
would prefer estrogen-free products to treat their condition. Of the women who had 
never used HT, 26% assumed their symptoms would go away over time.
Safety appears to be of paramount importance to this patient population, which is 





use HT. Also, the VVA market is substantially underserved. 
Less than a third of the potential patients are being treated, 
and a large number of those being treated could likely be 
convinced to use a product that has been demonstrated to 
be safer than HT. Even though the market is underserved, 
almost US$2 billion of HT is still sold annually in the USA 
alone.4 Vaginal HT, used exclusively for VVA, sold about 
US$500 million in 2008. Presently, local estrogen therapy, 
given as estrogen creams, vaginal estradiol tablets, and 
estrogen rings, is the treatment of choice for women with 
vaginal atrophy who do not have other menopausal symp-
toms, according to the 2010 NAMS guidelines.5
Generally, due to concerns about adverse effects of exog-
enous estrogens, there is growing interest in alternative thera-
pies for VVA. This interest has been the focus in menopausal 
women with breast cancer being treated with aromatase inhibi-
tors, who can experience a worsening of their VVA symptoms 
due to profound estradiol suppression.6 As more women living 
with breast cancer are being treated with aromatase inhibitor 
therapy, and these drugs move into a different adjuvant setting, 
such side effects are an increasing issue for women.
Third-generation aromatase inhibitors, which suppress 
circulating estrogen by more than 95%–97%, are more effec-
tive in reducing the risk of breast cancer recurrence than 
first-generation aromatase inhibitors, which reduce circulat-
ing estrogens by 90%. As local estrogens increase circulating 
estrogens, they may mitigate the effectiveness of the adjuvant 
therapy. Moreover, many women will not take estrogen therapy, 
including local estrogen therapy, because of real or perceived 
risks of the treatment. Thus, many women undergoing breast 
cancer treatment and related adjuvant therapy suffer diminished 
quality of life as they currently have no safe and effective 
treatment for their condition. Coupled with the pertinent recom-
mendations from the US Food and Drug Administration and 
NAMS Position Statement, there is a clear medical need for an 
effective “estrogen-free” alternative to treat VVA.
Alternative treatments
Currently, the 600,000 US women taking aromatase 
inhibitors report symptoms of VVA at about twice the 
rate of the general population. A population-based, cross-
sectional study on menopausal breast cancer patients on 
adjuvant endocrine treatment demonstrated that 57.6% of 
aromatase inhibitor–treated breast cancer patients rated 
vaginal atrophy symptoms as moderate/severe. Aromatase 
inhibitor–treated patients more often had an atrophic cyto-
hormonal evaluation (P , 0.05) and significantly higher 
vaginal pH (P , 0.05) than all control subjects.7 Overall, 
the authors agreed that because use of estradiol for relief 
may be problematic in these patients, research should 
focus on treatment options other than estradiol to allevi-
ate their symptoms of VVA. To date, alternative therapies 
have included selective estrogen receptor modulators 
(SERMs) and selective tissue estrogenic activity regulators 
(STEARs). There are several products currently in clinical 
development (Table 1).
The most advanced SERM product candidate is 
ospemifene (Ophena™), a novel orally delivered SERM to 
treat VVA developed by QuatRx™ Pharmaceuticals Com-
pany (Ann Arbor, MI). Ospemifene completed the second 
pivotal Phase III clinical trial and, according to QuatRx, 
achieved all endpoints. The results (N = 826) showed that 
ospemifene was statistically significantly (P , 0.001) 
superior to placebo in maturation index, vaginal pH, and 
“most bothersome” symptom (vaginal dryness or dys-
pareunia) with a 60 mg dose.8 Concerning dyspareunia, 
a daily 30 mg dose did not have a statistically significant 
effect compared with placebo, while a 60 mg dose reached 
significance. Women with an intact uterus were enrolled 
into an extension safety study where the treatment blind 
was maintained for 12 months. In this study, 83% taking 
60 mg daily completed the study compared with 69% on 
placebo. No trends were apparent in severe treatment-
emergent adverse events and there were no cases of venous 
thromboembolism, endometrial hyperplasia, or carcinoma.9 
A new drug application for ospemifene for the treatment 
of  VVA utilizing clinical trials that were conducted by 
QuatRx will be filed.
The most advanced STEAR product in clinical development 
by Pfizer, Inc (New York, NY) includes a   combination of oral 
Table 1 Alternative therapies for vulvovaginal atrophy in clinical development
Drug name Drug category Route of administration Pharmaceutical company Clinical phase
Ospemifene SeRM Oral QuatRx™ Pharmaceuticals Co, Ann Arbor, Mi NDA
BZA/Ce STeAR Oral Pfizer, Inc, New York, NY Phase iii
Prasterone® Androgen derivative vaginal endoCeutics, inc, Quebec, Canada Phase iii
Seale® SeRM vaginal Bionovo, inc, emeryville, CA Phase i–ii
Abbreviations: BZA/CE, bazedoxifene/conjugated estrogens; NDA, new drug application; SERM, selective estrogen receptor modulator; STEAR, selective tissue estrogenic 
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bazedoxifene (BZA) and conjugated estrogens (CE). Results 
of the 12-week (N = 652) Selective Estrogen Menopause and 
Response to Therapy 3 trial demonstrated improvement in the 
percent of superficial cells (P , 0.01) and vaginal pH (P , 0.05) 
at two BZA/CE doses (20 mg/0.45 mg, 20 mg/0.625 mg) 
compared with placebo and BZA   monotherapy.10 The largest 
(N = 3397) and longest (2 years) study of BZA/CE reported 
significantly improved VVA symptoms and demonstrated 
endometrial hyperplasia rates similar to that with placebo.11 
Longer-term safety with regard to cardiovascular and breast 
effects have not been established. Overall, the authors con-
cluded that the favorable efficacy and safety profiles of BZA/
CE support the use of a STEAR product containing BZA/CE 
as a new therapy for VVA in menopausal women.
Another product candidate in clinical development is 
  Prasterone® (EndoCeutics, Inc, Quebec, Canada). The intravag-
inal formulation containing dehydroepiandrosterone (DHEA) 
has completed a Phase III trial (N = 216). After 12 weeks, a 
significant increase in superficial cells (P , 0.0001) and a 
decrease in vaginal pH (P , 0.0001) were found. Comparable 
effects were observed at 0.25% (3.25 mg DHEA) and 1.0% 
(13 mg DHEA) doses.12 In another clinical trial (N = 114), the 
effects of Prasterone on the severity of dyspareunia on those 
who had identified it as their most bothersome symptom was 
studied. After 12 weeks of treatment, the severity score of 
pain during sexual activity decreased significantly even at the 
lowest dose (0.25%, 3.25 mg DHEA) when compared with 
the placebo group (P , 0.0001).13 A second Phase III clinical 
trial is underway (N = 345) using 0.25% (3.25 mg DHEA) and 
0.5% (6.5 mg DHEA) compared with placebo over 12 weeks.14 
Of concern, Prasterone is a precursor to estrogen and therefore 
must be converted to estrogen to be effective. Further safety 
studies are needed to determine if this is just another way of 
delivering exogenous estrogens.
Seala® (Bionovo, Inc, Emeryville, CA) is another poten-
tial product candidate. Seala appears to be a Chinese herbal 
extract selective to estrogen receptor beta and is in early 
development. A Phase II clinical trial (N = 217) using an 
oral formulation of the herbal extract decreased the   frequency 
of hot flashes compared with placebo after 12 weeks of 
treatment (P = 0.05).15 A randomized, blinded, placebo-
controlled, dose-escalating clinical trial in four cohorts of 
10 menopausal women (total N = 40) of a vaginal formula-
tion (VG-101) is expected to start soon (June 2012).16 Seala’s 
regulatory pathway is unclear.
A study (N = 90) currently underway will   measure 
the effects of the lowest doses (1/10 of the current 
therapeutic doses) of estradiol cream (10 mcg) or estriol 
cream (10 mcg) in the treatment of VVA.17 A randomized 
controlled trial with three arms, estradiol, estriol, and 
  placebo, will be conducted. The intervention will last for 12 
weeks. Outcomes will be measured, primarily, by the use of 
patient questionnaires and, secondarily, clinical examina-
tion scores. Safety will be evaluated with serum estrogen 
concentrations. All measures will be collected at baseline and 
at the termination of the study. Hormone concentrations will 
be collected, additionally, at week 2. This trial will answer 
important questions regarding the impact of very low doses 
of locally applied estrogens on symptoms of VVA. It will also 
give information about whether very low doses of estrogen 
creams, locally applied, result in systemic absorption.
Conclusion
Overall, it has been estimated that approximately 50% of 
menopausal women experience varying degrees of VVA. 
With the decline of the use of systemic HT, there is a greater 
need for effective, safe, and convenient local therapies 
to ameliorate symptoms of VVA. According to the latest 
evidence-based position statement of NAMS, there is a 
growing body of evidence that HT, regardless of route of 
administration and timing of delivery, has certain benefits and 
risks. Vaginal estrogen therapy is safe and well tolerated in 
menopausal women, though these conclusions are based on 
experience in small trials, largely of short duration. Further, 
in the absence of more rigorous studies suggesting otherwise, 
vaginal estrogens are not indicated for women receiving 
adjuvant aromatase inhibitor therapy for breast cancer. Thus, 
the safety of HT use in breast cancer survivors has not been 
fully established and there remains concern that it may be 
associated with an increased risk for breast cancer recurrence. 
Further research remains essential.5 The challenge is to find 
an alternative therapy that will maximize all the benefits of 
HT while minimizing all the risks. Therein lies the challenge 
for many years to come.
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